Stereotaxis, Inc. (STXS)
Dopo ore:
| Chiusura precedente | 2,1700 |
| Aperto | 2,1500 |
| Denaro | 2,2400 x 800 |
| Lettera | 2,3900 x 1100 |
| Min-Max giorno | 2,1000 - 2,2700 |
| Intervallo di 52 settimane | 1,5500 - 5,6400 |
| Volume | |
| Media Volume | 189.126 |
| Capitalizzazione | 169,897M |
| Beta (5 anni mensile) | 1,75 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,2000 |
| Prossima data utili | 10 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,86 |
- GlobeNewswire
Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System
ST. LOUIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of patients using the latest Genesis Robotic Magnetic Navigation (RMN) system by physicians of the nationally recognized Fred & Lena Meijer Heart Center, part of Corewell Health in Grand Rapids, Michigan. Electrophysiologists at Corewell Health have established a successful robotic cardiac ablation prog
- GlobeNewswire
Stereotaxis to Participate in Piper Sandler 34th Annual Healthcare Conference
ST. LOUIS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 34th Annual Healthcare Conference. Mr. Fischel will present on Stereotaxis’ business and technology during a Fireside Discussion on Thursday, December 1, 2022, at 9:00 am ET. He will then join a panel discussion on “The Future of Robotic
- GlobeNewswire
Stereotaxis Reports 2022 Third Quarter Financial Results
ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022. “Stereotaxis continues to demonstrate robust commercial and technological progress,” said David Fischel, Chairman and CEO. “We received two system orders in the third quarter, and have already received two additional signed purchase contracts as we
